138 related articles for article (PubMed ID: 8673135)
1. Mad-related genes in the human.
Riggins GJ; Thiagalingam S; Rozenblum E; Weinstein CL; Kern SE; Hamilton SR; Willson JK; Markowitz SD; Kinzler KW; Vogelstein B
Nat Genet; 1996 Jul; 13(3):347-9. PubMed ID: 8673135
[TBL] [Abstract][Full Text] [Related]
2. DPC4 (SMAD4) mediates transforming growth factor-beta1 (TGF-beta1) induced growth inhibition and transcriptional response in breast tumour cells.
de Winter JP; Roelen BA; ten Dijke P; van der Burg B; van den Eijnden-van Raaij AJ
Oncogene; 1997 Apr; 14(16):1891-9. PubMed ID: 9150356
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the MADH2/Smad2 gene, a human Mad homolog responsible for the transforming growth factor-beta and activin signal transduction pathway.
Takenoshita S; Mogi A; Nagashima M; Yang K; Yagi K; Hanyu A; Nagamachi Y; Miyazono K; Hagiwara K
Genomics; 1998 Feb; 48(1):1-11. PubMed ID: 9503010
[TBL] [Abstract][Full Text] [Related]
4. Combined copy status of 18q21 genes in colorectal cancer shows frequent retention of SMAD7.
Boulay JL; Mild G; Reuter J; Lagrange M; Terracciano L; Lowy A; Laffer U; Orth B; Metzger U; Stamm B; Martinoli S; Herrmann R; Rochlitz C
Genes Chromosomes Cancer; 2001 Jul; 31(3):240-7. PubMed ID: 11391794
[TBL] [Abstract][Full Text] [Related]
5. A human Mad protein acting as a BMP-regulated transcriptional activator.
Liu F; Hata A; Baker JC; Doody J; Cárcamo J; Harland RM; Massagué J
Nature; 1996 Jun; 381(6583):620-3. PubMed ID: 8637600
[TBL] [Abstract][Full Text] [Related]
6. Mutational analysis of TGF-beta type II receptor, Smad2, Smad3, Smad4, Smad6 and Smad7 genes in colorectal cancer.
Fukushima T; Mashiko M; Takita K; Otake T; Endo Y; Sekikawa K; Takenoshita S
J Exp Clin Cancer Res; 2003 Jun; 22(2):315-20. PubMed ID: 12866583
[TBL] [Abstract][Full Text] [Related]
7. Smad2 and Smad4 gene mutations in hepatocellular carcinoma.
Yakicier MC; Irmak MB; Romano A; Kew M; Ozturk M
Oncogene; 1999 Aug; 18(34):4879-83. PubMed ID: 10490821
[TBL] [Abstract][Full Text] [Related]
8. Receptor-associated Mad homologues synergize as effectors of the TGF-beta response.
Zhang Y; Feng X; We R; Derynck R
Nature; 1996 Sep; 383(6596):168-72. PubMed ID: 8774881
[TBL] [Abstract][Full Text] [Related]
9. Analysis of specific gene mutations in the transforming growth factor-beta signal transduction pathway in human ovarian cancer.
Wang D; Kanuma T; Mizunuma H; Takama F; Ibuki Y; Wake N; Mogi A; Shitara Y; Takenoshita S
Cancer Res; 2000 Aug; 60(16):4507-12. PubMed ID: 10969799
[TBL] [Abstract][Full Text] [Related]
10. SMAD4 mutations in colorectal cancer probably occur before chromosomal instability, but after divergence of the microsatellite instability pathway.
Woodford-Richens KL; Rowan AJ; Gorman P; Halford S; Bicknell DC; Wasan HS; Roylance RR; Bodmer WF; Tomlinson IP
Proc Natl Acad Sci U S A; 2001 Aug; 98(17):9719-23. PubMed ID: 11481457
[TBL] [Abstract][Full Text] [Related]
11. Distortion of autocrine transforming growth factor beta signal accelerates malignant potential by enhancing cell growth as well as PAI-1 and VEGF production in human hepatocellular carcinoma cells.
Sugano Y; Matsuzaki K; Tahashi Y; Furukawa F; Mori S; Yamagata H; Yoshida K; Matsushita M; Nishizawa M; Fujisawa J; Inoue K
Oncogene; 2003 Apr; 22(15):2309-21. PubMed ID: 12700666
[TBL] [Abstract][Full Text] [Related]
12. No SMAD4 hypermethylation in colorectal cancer.
Roth S; Laiho P; Salovaara R; Launonen V; Aaltonen LA
Br J Cancer; 2000 Oct; 83(8):1015-9. PubMed ID: 10993648
[TBL] [Abstract][Full Text] [Related]
13. Frequency of Smad gene mutations in human cancers.
Riggins GJ; Kinzler KW; Vogelstein B; Thiagalingam S
Cancer Res; 1997 Jul; 57(13):2578-80. PubMed ID: 9205057
[TBL] [Abstract][Full Text] [Related]
14. Functional consequences of tumorigenic missense mutations in the amino-terminal domain of Smad4.
Morén A; Itoh S; Moustakas A; Dijke P; Heldin CH
Oncogene; 2000 Sep; 19(38):4396-404. PubMed ID: 10980615
[TBL] [Abstract][Full Text] [Related]
15. Smad4-independent regulation of p21/WAF1 by transforming growth factor-beta.
Ijichi H; Otsuka M; Tateishi K; Ikenoue T; Kawakami T; Kanai F; Arakawa Y; Seki N; Shimizu K; Miyazono K; Kawabe T; Omata M
Oncogene; 2004 Feb; 23(5):1043-51. PubMed ID: 14762439
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers.
Thiagalingam S; Lengauer C; Leach FS; Schutte M; Hahn SA; Overhauser J; Willson JK; Markowitz S; Hamilton SR; Kern SE; Kinzler KW; Vogelstein B
Nat Genet; 1996 Jul; 13(3):343-6. PubMed ID: 8673134
[TBL] [Abstract][Full Text] [Related]
17. TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4.
Nakao A; Imamura T; Souchelnytskyi S; Kawabata M; Ishisaki A; Oeda E; Tamaki K; Hanai J; Heldin CH; Miyazono K; ten Dijke P
EMBO J; 1997 Sep; 16(17):5353-62. PubMed ID: 9311995
[TBL] [Abstract][Full Text] [Related]
18. Tumor-derived C-terminal mutations of Smad4 with decreased DNA binding activity and enhanced intramolecular interaction.
Kuang C; Chen Y
Oncogene; 2004 Feb; 23(5):1021-9. PubMed ID: 14647410
[TBL] [Abstract][Full Text] [Related]
19. Smad6 inhibits signalling by the TGF-beta superfamily.
Imamura T; Takase M; Nishihara A; Oeda E; Hanai J; Kawabata M; Miyazono K
Nature; 1997 Oct; 389(6651):622-6. PubMed ID: 9335505
[TBL] [Abstract][Full Text] [Related]
20. Acceleration of Smad2 and Smad3 phosphorylation via c-Jun NH(2)-terminal kinase during human colorectal carcinogenesis.
Yamagata H; Matsuzaki K; Mori S; Yoshida K; Tahashi Y; Furukawa F; Sekimoto G; Watanabe T; Uemura Y; Sakaida N; Yoshioka K; Kamiyama Y; Seki T; Okazaki K
Cancer Res; 2005 Jan; 65(1):157-65. PubMed ID: 15665291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]